Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 上海联影医疗科技股份有限公司致力于为全球客户提供高性能医学影像设备、放射治疗产品、生命科学仪器及医疗数字化、智能化解决方案。自设立以来，公司持续进行高强度研发投入，致力于攻克医学影像设备、放射治疗产品等大型医疗装备领域的核心技术；经过多年努力，公司已经构建包括医学影像设备、放射治疗产品、生命科学仪器在内的完整产品线布局。公司已牵头承担近40项国家级及省级研发项目，包括近20项国家级科技重大专项，并荣获2020年度国家科学技术进步奖一等奖、2020年度上海市科技进步奖一等奖、上海市重点产品质量攻关成果奖（2020年）一等奖、第21届中国国际工业博览会大奖、中国专利优秀奖、第十八届中国专利金奖、2017年中国商标金奖等众多荣誉奖项。
Main Business 为全球客户提供高性能医学影像设备、放射治疗产品、生命科学仪器及医疗数字化、智能化解决方案
Legal Representative 张强
Top Executives
董事长：张强
董事：GUOSHENG TAN,丁君,TAO CAI,JUN BAO,沈思宇
独立董事：JIAHONG GAO,王少飞,盛雷鸣
Top 5 Shareholder
Shareholder name Nature Holding Date
联影医疗技术集团有限公司限售股20.33%30/09/2024
上海联和投资有限公司流通A股16.38%30/09/2024
上海影升投资合伙企业（有限合伙）限售股7.30%30/09/2024
上海中科道富投资合伙企业（有限合伙）流通A股5.03%30/09/2024
上海北元投资合伙企业（有限合伙）流通A股3.50%30/09/2024
Company Secretary TAO CAI
Solicitors 上海市通力律师事务所
Auditors 容诚会计师事务所（特殊普通合伙）;普华永道中天会计师事务所（特殊普通合伙）
Tel No 021-67076658
Fax No 021-67076659
Website www.united-imaging.com
Email IR@united-imaging.com
Company Address
Register: 上海市嘉定区城北路2258号
Office: 上海市嘉定区城北路2258号
Listing Date 22/08/2022
Shares Capital
Shares Capital: 824,157,988
Total A Share: 824,157,988
Listed A Share: 593,298,976
Non-tradable A Share: 230,859,012
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 2.400
DPS(RMB)* ¥ 0.250
NBV Per Share(RMB)* ¥ 22.892
Market Capitalization(RMB) 79.799B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.